Chordate Medical has now completed the training of clinic staff and assisted in the initiation of treatment for the first three patients at the private clinic in Hamburg, which is the first commercial customer in Germany for Ozilia migraine treatment. Chordate and the clinic signed an agreement in November 2023 for the installation of Chordate's drug-free alternative for preventive migraine treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0548 SEK | +0.74% | -14.38% | -65.84% |
07/05 | Chordate Medical Receives Patent Approval in the US | CI |
22/03 | Chordate Medical Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-65.84% | 2.5M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- CMH Stock
- News Chordate Medical Holding AB
- Chordate Medical Completes Training of Clinic Staff and Assists in Initiation of Treatment for First Three Patients at the Private Clinic in Hamburg